Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...
Add Yahoo as a preferred source to see more of our stories on Google. This image provided by Bristol Myers Squibb in October 2024 shows the company's drug Cobenfy, which the U.S. Food and Drug ...
Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development of Cobenfy (xanomeline-trospium), the first truly novel medication for ...
Bristol Myers’ BMY schizophrenia drug Cobenfy delivered a sound performance in 2025. Cobenfy (xanomeline and trospium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results